论文部分内容阅读
目的探讨环氧合酶-2(COX-2)与血管内皮生长因子(VEGF)在非小细胞肺癌(NSCLC)中的表达及其与生物学行为的关系。方法58例临床资料完整的肺癌手术切除标本,采用免疫组化方法检测其中COX-2、VEGF及微血管密度(MVD)的表达情况。结果58例Nsclc的COX-2阳性表达率75.9%(44/58),VEGF的阳性表达率82.7%(48/58),临床分期高的COX-2,VEGF表达及MVD计数要高于临床分期低的肺癌,有淋巴结转移的COX-2,VEGF的表达及MVD计数要高于无淋巴结转移的肺癌组织,差别均具有统计学意义(P<0.05),并且COX-2的表达与VEGF、CD34的表达成正相关。结论COX-2、VEGF在人肺癌组织中均有高表达,COX-2、VEGF和MVD三者在肿瘤血管生成及肿瘤浸润转移中可能起协同作用,可作为评价NSCLC预后的共同指标。
Objective To investigate the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC) and its relationship with biological behavior. Methods Fifty-eight surgical specimens of lung cancer were collected. The expression of COX-2, VEGF and microvessel density (MVD) were detected by immunohistochemistry. Results The positive expression rate of COX-2 in 58 cases was 75.9% (44/58), the positive expression rate of VEGF was 82.7% (48/58). The high clinical stage COX-2, VEGF expression and MVD count were higher than clinical stage The expression of COX-2, VEGF and MVD in patients with low grade lung cancer, lymph node metastasis and MVD were higher than those without lymph node metastasis (P <0.05), and the expressions of COX-2 and VEGF, CD34 The expression of positive correlation. Conclusions Both COX-2 and VEGF are highly expressed in human lung cancer tissues. COX-2, VEGF and MVD may play synergistic roles in tumor angiogenesis and tumor invasion and metastasis, which may serve as a common indicator for evaluating the prognosis of NSCLC.